SMS Pharmaceuticals logo

SMSPHARMA - SMS Pharmaceuticals Share Price

₹148.75 -2.4  -1.6%

Last Trade - 14/10/21

Small Cap
Market Cap £122.8m
Enterprise Value £140.6m
Revenue £59.8m
Position in Universe 933rd / 3160
Unlock SMSPHARMA Revenue
Relative Strength (%)
1m -11.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2016 2017 2018 2019 2020 2021 2022E 2023E CAGR / Avg
6,032 4,467 4,649 4,649 4,119 5,632 -1.4%
+16.0 -30.3 +11.5 +26.0 -21.1 +97.8
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2021, SMSPharmaceuticals Ltd revenues increased 44% to RS1.63B. Netincome increased from RS70.3M to RS235.6M. Revenues reflectan increase in demand for the Company's products andservices due to favorable market conditions. Net incomebenefited from Share of Profit/ (Loss) in associate comincrease from RS21.8M (losses) to RS3.6M (earnings), OtherIncome increase from RS4M to RS12.9M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


SMSPHARMA Revenue Unlock SMSPHARMA Revenue

Net Income

SMSPHARMA Net Income Unlock SMSPHARMA Revenue

Normalised EPS

SMSPHARMA Normalised EPS Unlock SMSPHARMA Revenue

PE Ratio Range

SMSPHARMA PE Ratio Range Unlock SMSPHARMA Revenue

Dividend Yield Range

SMSPHARMA Dividend Yield Range Unlock SMSPHARMA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SMSPHARMA EPS Forecasts Unlock SMSPHARMA Revenue
Profile Summary

SMS Pharmaceuticals Limited is engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and their intermediates. The Company's principal products/services include pharmaceuticals. The Company's product range includes API and intermediates. The Company offers a range of anti-ulcer, anti-fungal, anti-migraine, anti-hypertensive and other API products, which include Famotidine USP/Ph.Eur/JP, Lanoconazole USP/JP, Sumatriptan Base USP, Imidapril Hcl and Ondansetron Hcl USP/Ph.Eur. The Company also offers a range of erectile dysfunction, anti-cancer, anti-viral and pulmonary arterial hypertension intermediate products, which include Ranitidine, Famotidine, Rizatriptan, Eletriptan HBr, Imidapril, Perindopril, Sildenafil citrate, Tadalafil, Imatinib and Lopinavir. The Company's plants are located in Telangana and Andhra Pradesh in India.

Last Annual March 31st, 2021
Last Interim June 30th, 2021
Incorporated December 14, 1987
Public Since February 25, 2007
No. of Shareholders: 19,878
No. of Employees: 1,011
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 84,652,030
Free Float (0.0%)
Eligible for
SMSPHARMA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SMSPHARMA
Upcoming Events for SMSPHARMA
Frequently Asked Questions for SMS Pharmaceuticals
What is the SMS Pharmaceuticals share price?

As of 14/10/21, shares in SMS Pharmaceuticals are trading at ₹148.75, giving the company a market capitalisation of £122.8m. This share price information is delayed by 15 minutes.

How has the SMS Pharmaceuticals share price performed this year?

Shares in SMS Pharmaceuticals are currently trading at ₹148.75 and the price has moved by 68.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the SMS Pharmaceuticals price has moved by 5.68% over the past year.

What are the analyst and broker recommendations for SMS Pharmaceuticals?

Of the analysts with advisory recommendations for SMS Pharmaceuticals, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for SMS Pharmaceuticals is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will SMS Pharmaceuticals next release its financial results?

SMS Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the SMS Pharmaceuticals dividend yield?

The SMS Pharmaceuticals dividend yield is 0.2% based on the trailing twelve month period.

Does SMS Pharmaceuticals pay a dividend?

Last year, SMS Pharmaceuticals paid a total dividend of 0.3, and it currently has a trailing dividend yield of 0.2%. Looking ahead, SMS Pharmaceuticals has not announced an ex-dividend date yet and the next dividend pay date is 2021-11-01.

When does SMS Pharmaceuticals next pay dividends?

SMS Pharmaceuticals has yet to annouce their ex-dividend date and the next dividend pay date is 2021-11-01. The historic dividend yield on SMS Pharmaceuticals shares is currently 0.2%.

How do I buy SMS Pharmaceuticals shares?

To buy shares in SMS Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of SMS Pharmaceuticals?

Shares in SMS Pharmaceuticals are currently trading at ₹148.75, giving the company a market capitalisation of £122.8m.

Where are SMS Pharmaceuticals shares listed? Where are SMS Pharmaceuticals shares listed?

Here are the trading details for SMS Pharmaceuticals:

Country of listing: India
Exchange: NSI
Ticker Symbol: SMSPHARMA
What kind of share is SMS Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, SMS Pharmaceuticals is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a SMS Pharmaceuticals share price forecast 2021?

We were not able to load any forecast data for SMS Pharmaceuticals.

How can I tell whether the SMS Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SMS Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -17.59%. At the current price of ₹148.75, shares in SMS Pharmaceuticals are trading at -1.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the SMS Pharmaceuticals PE Ratio?

The SMS Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 15.91. The shares are currently trading at ₹148.75.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of SMS Pharmaceuticals?

SMS Pharmaceuticals's management team is headed by:

Ramesh Potluri - CHM
N. Rajendra Prasad - CFO
P. Sharath Kumar - NID
Thummala Neelaveni - NID
P. Rao - IND
Vudari Venkatish - CCO
Shravan Kudaravalli - DRC
Shilpa Waghmare - NED
Vamsi Potluri - EDR
Who are the major shareholders of SMS Pharmaceuticals?

Here are the top five shareholders of SMS Pharmaceuticals based on the size of their shareholding:

Potluri (Ramesh Babu) Individual Investor
Percentage owned: 18.37% (15.6m shares)
Potluri (Hima Bindu) Individual Investor
Percentage owned: 17.47% (14.8m shares)
Potluri (Vamsi Krishna) Individual Investor
Percentage owned: 15.74% (13.3m shares)
Potluri Infra Projects Pvt. Ltd. Corporation
Percentage owned: 8.68% (7.35m shares)
Potluri (Trilok) Individual Investor
Percentage owned: 2.58% (2.19m shares)
Similar to SMSPHARMA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.